Prevalence of high-risk human papillomavirus genotypes and viral load correlated with squamous cell inflammation among women in Gabon.
Correlation
HR-HPV
Prevalence
Squamous cell inflammation
Viral load
Women of Gabon
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
12 Oct 2024
12 Oct 2024
Historique:
received:
05
09
2024
accepted:
08
10
2024
medline:
13
10
2024
pubmed:
13
10
2024
entrez:
12
10
2024
Statut:
epublish
Résumé
High-risk genotypes of Human Papillomavirus are responsible for 90% of cases of cervical cancer worldwide. Inflammation of squamous cells is mainly linked to HPV. In Gabon, HPV is endemic and circulates among the female population. The study aimed to determine the prevalence of HR-HPV genotypes and to investigate the correlation between squamous cell inflammation and HPV viral load in infected women in Gabon. The cross-sectional study was conducted at Libreville University Hospital Center (UHC) and National Public Health Laboratory from March to May 2024 among 399 women. Two cervical smears were taken. Genotype detection was carried out by multiplex fluorescence real-time PCR in the NPHL virology unit. Cytology was carried out in UHC's anatomic-pathology laboratory. Data were analyzed by SPSS software. Graphs were plotted using Microsoft Excel 2016. The prevalence of Human Papillomavirus was 26.1% (95% CI: 22-30.6). The prevalence of HR-HPV genotypes was 24.8%. The most common HR-HPV genotypes were HPV-16/52/18/35/56/58/53/68. The rate of multiple HPV infections was 29.8% and 95.2% for the HR-HPV infection rate. Viral load was significantly correlated with squamous cell inflammation (r = 0.977 and P = 0.001). HR-HPV infection remains a concern in women, however early screening is necessary for optimal monitoring and management. HR-HPV viral load is a predictive marker of squamous cell inflammation.
Sections du résumé
BACKGROUND
BACKGROUND
High-risk genotypes of Human Papillomavirus are responsible for 90% of cases of cervical cancer worldwide. Inflammation of squamous cells is mainly linked to HPV. In Gabon, HPV is endemic and circulates among the female population. The study aimed to determine the prevalence of HR-HPV genotypes and to investigate the correlation between squamous cell inflammation and HPV viral load in infected women in Gabon.
METHODS
METHODS
The cross-sectional study was conducted at Libreville University Hospital Center (UHC) and National Public Health Laboratory from March to May 2024 among 399 women. Two cervical smears were taken. Genotype detection was carried out by multiplex fluorescence real-time PCR in the NPHL virology unit. Cytology was carried out in UHC's anatomic-pathology laboratory. Data were analyzed by SPSS software. Graphs were plotted using Microsoft Excel 2016.
RESULTS
RESULTS
The prevalence of Human Papillomavirus was 26.1% (95% CI: 22-30.6). The prevalence of HR-HPV genotypes was 24.8%. The most common HR-HPV genotypes were HPV-16/52/18/35/56/58/53/68. The rate of multiple HPV infections was 29.8% and 95.2% for the HR-HPV infection rate. Viral load was significantly correlated with squamous cell inflammation (r = 0.977 and P = 0.001).
CONCLUSION
CONCLUSIONS
HR-HPV infection remains a concern in women, however early screening is necessary for optimal monitoring and management. HR-HPV viral load is a predictive marker of squamous cell inflammation.
Identifiants
pubmed: 39396007
doi: 10.1186/s12905-024-03403-6
pii: 10.1186/s12905-024-03403-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
561Informations de copyright
© 2024. The Author(s).
Références
Choi S, Ismail A, Pappas-Gogos G, Boussios S. HPV and cervical cancer: review of epidemiology and screening in the United Kingdom. Pathogens. 2023;12(2):298. https://doi.org/10.3390/pathogens12020298 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.3390/pathogens12020298
pubmed: 36839570
World Health Organization. (2021). Cervical cancer: Key facts. Retrieved on 09/06/2023 from https://www.who.int/fr/news-room/fact-sheets/detail/cervical-cancer (2021).
Zhao C, Zhao Y, Li J, Li M, Shi Y, Wei L. Opportunities and challenges for human papillomavirus vaccination in China. Hum Vaccin Immunother. 2024;20(1):2329450. [Pubmed] [Google scholar] [CrossRef].
doi: 10.1080/21645515.2024.2329450
pubmed: 38575524
pmcid: 10996835
Anoruo O, Bristow C, Mody N, Klausner JD. Estimated prevalence of human papillomavirus among Nigerian women: a systematic review and meta-analysis. Afr J Reprod Health. 2022;26(6):89–96. https://doi.org/10.29063/ajrh2022/v26i6.10 . [Pubmed] [Google scholar].
doi: 10.29063/ajrh2022/v26i6.10
pubmed: 37585061
Awua AK, Sackey ST, Osei YD, Asmah RH, Wiredu EK. Prevalence of human papillomavirus genotypes among women with cervical cancer in Ghana. Infect Agents Cancer. 2016;11(1). https://doi.org/10.1186/s13027-016-0050-4 . [Pubmed] [Google scholar] [CrossRef].
Mbulawa ZZA, Somdyala NI, Mabunda SA, Williamson AL. High human papillomavirus prevalence among females attending high school in the Eastern Cape Province of South Africa. Angeletti PC, editor. PLOS ONE. 2021;16(6):e0253074. https://doi.org/10.1371/journal.pone.0253074 [Pubmed] [Google scholar] [CrossRef].
Tagne Simo R, Djoko Nono AG, Fogang Dongmo HP, Seke Etet PF, Fonyuy BK, Kamdje AHN, et al. Prevalence of precancerous cervical lesions and high-risk human papillomavirus types in Yaounde, Cameroon. J Infect Developing Ctries. 2021;15(09):1339–45. https://doi.org/10.3855/jidc.15218 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.3855/jidc.15218
Alzaquzi H, Almaghur L, Eshagrouni A, Elahmer O, Bashein A. Prevalence of high-risk human papillomavirus types 16 and 18 among Libyan women in Tripoli libya. Libyan J Med Sci. 2019;3(4):125. https://doi.org/10.4103/ljms.ljms_44_19 . [Google scholar] [CrossRef].
doi: 10.4103/ljms.ljms_44_19
Wang J, Tang D, Wang J, Zhang Z, Chen Y, Wang K, et al. Genotype distribution and prevalence of human papillomavirus among women with cervical cytological abnormalities in Xinjiang, China. Hum Vaccines Immunotherapeutics. 2019;15(7–8):1889–96. https://doi.org/10.1080/21645515.2019.1578598 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1080/21645515.2019.1578598
Bräutigam K, Meier S, Meneder S, Proppe L, Stroschein K, Polack S, et al. Distribution of HPV subtypes in diverse anogenital and oral samples from women and correlation of infections with neoplasia of the cervix. Cancers (Basel). 2022;14(13):3136. https://doi.org/10.3390/cancers14133136 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.3390/cancers14133136
pubmed: 35804905
Rezaee Azhar I, Yaghoobi M, Mossalaeie MM, Kollaee Darabi A, Nejadeh AH, Jamshidi M, et al. Prevalence of human papilloma virus (HPV) genotypes between outpatients males and females referred to seven laboratories in Tehran, Iran. Infect Agents Cancer. 2022;17(1). https://doi.org/10.1186/s13027-022-00421-7 . [Pubmed] [Google scholar] [CrossRef].
Long T, Long L, Chen Y, Li Y, Tuo Y, Hu Y, et al. Severe cervical inflammation and high-grade squamous intraepithelial lesions: a cross-sectional study. Archives Gynecol Obstet. 2020;303(2):547–56. https://doi.org/10.1007/s00404-020-05804-y . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1007/s00404-020-05804-y
Sadri Nahand J, Moghoofei M, Salmaninejad A, Bahmanpour Z, Karimzadeh M, Nasiri M, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: a review. Int J Cancer. 2020;146(2):305–20. [Pubmed] [Google scholar] [CrossRef].
doi: 10.1002/ijc.32688
pubmed: 31566705
Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50. https://doi.org/10.1186/s12199-018-0740-1 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1186/s12199-018-0740-1
pubmed: 30340457
pmcid: 6195709
Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2019;40(5):602–8. https://doi.org/10.1080/01443615.2019.1634030 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1080/01443615.2019.1634030
pubmed: 31500479
pmcid: 7062568
Moussavou-Boundzanga P, Koumakpayi IH, Engohan Aloghe C, Chansi JK, Revignet R, Leroy EM, et al. HPV genotypes in high-grade cervical lesions and invasive cervical carcinoma detected in Gabonese women. Infect Agent Cancer. 2023;18(1):16. https://doi.org/10.1186/s13027-023-00493-z . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1186/s13027-023-00493-z
pubmed: 36890547
pmcid: 9994388
Woromogo SH, Ambounda Ledaga N, Yagata-Moussa FE, Mihindou AS. Uterine cervical neoplasms mass screening at the University Hospital Centre of Libreville, Gabon: Associated factors with precancerous and cancerous lesions. PLoS ONE. 2021;16(7):e0255289. https://doi.org/10.1371/journal.pone.0255289 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1371/journal.pone.0255289
pubmed: 34297784
pmcid: 8301670
National Cancer Institute. Dictionary of cancer terms. Accessed on September 21. 2024 in https://www.cancer.gov/publications/dictionaries/cancer-terms . 2023.
Ali MAM, Bedair RN, Abd El Atti RM. Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: prevalence, type‐specific distribution, and correlation with cervical cytology. Cancer Cytopathol. 2019;127(9):567–77. https://doi.org/10.1002/cncy.22165 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1002/cncy.22165
pubmed: 31390155
Doh G, Mkong E, Ikomey GM, Obasa AE, Mesembe M, Fokunang C, et al. Preinvasive cervical lesions and high prevalence of human papilloma virus among pregnant women in Cameroon. GERMS. 2021;11(1):78–87. https://doi.org/10.18683/germs.2021.1243 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.18683/germs.2021.1243
pubmed: 33898344
Salambanga C, Zohoncon TM, Traoré IMA, Ouedraogo RA, Djigma WF, Ouédraog C, et al. High prevalence of high-risk human papillomavirus (HPV) infection among sexually active women in Ouagadougou. Med Sante Trop. 2019;29(3):302–5. [Pubmed] [Google scholar] [CrossRef].
pubmed: 31573526
Mutombo AB, Benoy I, Tozin R, Bogers J, Van geertruyden JP, Jacquemyn Y. Prevalence and distribution of human papillomavirus genotypes among women in Kinshasa, the Democratic Republic of the Congo. J Global Oncol. 2019;51–9. https://doi.org/10.1200/jgo.19.00110 . [Pubmed] [Google scholar] [CrossRef].
Nyasenu YT, Gbeasor-Komlanvi FA, Ehlan A, Issa SAR, Dossim S, Kolou M et al. Prevalence and distribution of Human Papillomavirus (HPV) genotypes among HIV infected women in Lomé, Togo. Charpentier C, editor. PLOS ONE. 2019;14(2):e0212516. https://doi.org/10.1371/journal.pone.0212516 [Pubmed] [Google scholar] [CrossRef].
Sosso SM, Tchouaket MCT, Fokam J, Simo RK, Torimiro J, Tiga A, et al. Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon. Virol J. 2020;17(1). https://doi.org/10.1186/s12985-020-01340-y . [Pubmed] [Google scholar] [CrossRef].
Nejo YT, Olaleye DO, Odaibo GN. Molecular characterisation of genital human papillomavirus among women in Southwestern, Nigeria. Blackard J, editor. PLOS ONE. 2019;14(11):e0224748. https://doi.org/10.1371/journal.pone.0224748 [Pubmed] [Google scholar] [CrossRef].
Colpani V, Soares Falcetta F, Bacelo Bidinotto A, Kops NL, Falavigna M, Serpa Hammes L, et al. Prevalence of human papillomavirus (HPV) in Brazil: a systematic review and meta-analysis. PLoS ONE. 2020;15(2):e0229154. https://doi.org/10.1371/journal.pone.0229154 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1371/journal.pone.0229154
pubmed: 32084177
pmcid: 7034815
Ge Y, Zhong S, Ren M, Ge Y, Mao Y, Cao P. Prevalence of human papillomavirus infection of 65,613 women in East China. BMC Public Health. 2019;19(1). https://doi.org/10.1186/s12889-019-6487-9 . [Pubmed] [Google scholar] [CrossRef].
Ardhaoui M, Letaief H, Ennaifer E, Bougatef S, Lassili T, Bel Haj Rhouma R, et al. The prevalence, genotype distribution and risk factors of human papillomavirus in Tunisia: a national-based study. Viruses. 2022;14(10):2175. https://doi.org/10.3390/v14102175 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.3390/v14102175
pubmed: 36298732
Huang W, Xu H, Hu H, Zhang D, Liu Y, Guo Y, et al. The prevalence of human papillomavirus among women in northern Guangdong Province of China. Sci Rep. 2022;12(1). https://doi.org/10.1038/s41598-022-17632-y . [Pubmed] [Google scholar] [CrossRef].
Mai Q, Yang X, Cheng H, Wu G, Wu Z. Prevalence and genotype distribution of human papillomavirus among women with cervical lesions in Shenzhen city, China. Hum Vaccin Immunother. 2021;17(4):965–71. [Pubmed] [Google scholar] [CrossRef].
doi: 10.1080/21645515.2020.1805993
pubmed: 32961080
Tchouaket MCT, Fokam J, Sosso SM, Semengue ENJ, Yagai B, Simo RK, et al. High genotypic diversity of human papillomavirus among women in Cameroon: implications for vaccine effectiveness. IJID Reg. 2022;5:130–6. https://doi.org/10.1016/j.ijregi.2022.09.014 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1016/j.ijregi.2022.09.014
pubmed: 36313603
pmcid: 9596729
Donkoh ET, Asmah RH, Agyemang-Yeboah F, Dabo EO, Wiredu EK. Prevalence and distribution of vaccine-preventable Genital Human Papillomavirus(HPV) genotypes in Ghanaian Women presenting for screening. Cancer Control. 2022;29. https://doi.org/10.1177/10732748221094721 . [Pubmed] [Google scholar] [CrossRef].
Aimagambetova G, Babi A, Issanov A, Akhanova S, Udalova N, Koktova S, Balykov A, Sattarkyzy Z, Abakasheva Z, Azizan A, Chan CK, Issa T. The distribution and prevalence of high-risk HPV genotypes other than HPV-16 and HPV-18 among women attending gynecologists’ offices in Kazakhstan. Biology (Basel). 2021;10(8):794. [Pubmed] [Google scholar] [CrossRef].
pubmed: 34440026
Mboumba Bouassa RS, Nodjikouambaye ZA, Sadjoli D, Adawaye C, Péré H, Veyer D, et al. High prevalence of cervical high-risk human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N’Djamena, Chad. PLoS ONE. 2019;14(6):e0217486. https://doi.org/10.1371/journal.pone.0217486 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1371/journal.pone.0217486
pubmed: 31158254
pmcid: 6546217
Taskin MH, Nursal AF, Oruc MA, Kariptas E. Genotype distribution and prevalence of high-risk human papillomavirus infection among women in Samsun Province of Turkey. Asian Pac J Cancer Prev. 2022;23(7):2477–82. [Pubmed] [Google scholar] [CrossRef].
doi: 10.31557/APJCP.2022.23.7.2477
pubmed: 35901356
pmcid: 9727355
Muresu N, Sotgiu G, Marras S, Gentili D, Sechi I, Cossu A, et al. Cervical screening in North Sardinia (Italy): genotype distribution and prevalence of HPV among women with ASC-US Cytology. Int J Environ Res Public Health. 2022;19(2):693. https://doi.org/10.3390/ijerph19020693 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.3390/ijerph19020693
pubmed: 35055515
pmcid: 8775344
Tsimba Lemba PC, Boumba LMA, Péré H, Nganga PC, Veyer D, Puech J, et al. Human papillomavirus genotype distribution by cytological status and associated risk factors in the general population of Congolese women living in urban and rural areas: implications for cervical cancer prevention. Infect Dis Now. 2023;53(8):104762. https://doi.org/10.1016/j.idnow.2023.104762 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1016/j.idnow.2023.104762
pubmed: 37454761
Li M, Du X, Lu M, Zhang W, Sun Z, Li L, et al. Prevalence characteristics of single and multiple HPV infections in women with cervical cancer and precancerous lesions in Beijing, China. J Med Virol. 2019;91(3):473–81. [Pubmed] [Google scholar] [CrossRef].
doi: 10.1002/jmv.25331
pubmed: 30281807
Liu Y, Xu C, Pan J, Sun C, Zhou H, Meng Y. Significance of the viral load of high-risk HPV in the diagnosis and prediction of cervical lesions: a retrospective study. BMC Women’s Health. 2021;21(1):353. https://doi.org/10.1186/s12905-021-01493-0 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.1186/s12905-021-01493-0
pubmed: 34625069
pmcid: 8501737
Lu X, Wang T, Zhang Y, Liu Y. Analysis of influencing factors of viral load in patients with high-risk human papillomavirus. Virology Journal. 2021;18(1). https://doi.org/10.1186/s12985-020-01474-z [Pubmed] [Google scholar] [CrossRef].
Chen L, Dong B, Zhang Q, Mao X, Lin W, Ruan G et al. HR-HPV viral load quality detection provide more accurate prediction for residual lesions after treatment: a prospective cohort study in patients with high-grade squamous lesions or worse. Medical Oncology. 2020;37(5). https://doi.org/10.1007/s12032-020-01363-z [Pubmed] [Google scholar] [CrossRef].
Wang M, Hou B, Wang X, Han L, Shi Y, Zhang Y et al. Diagnostic value of high-risk human papillomavirus viral load on cervical lesion assessment and ASCUS triage. Cancer Medicine. 2021;10(7):2482–8. https://doi.org/10.1002/cam4.3653 [Pubmed] [Google scholar] [CrossRef].
Hemmat N, Bannazadeh Baghi H. Association of human papillomavirus infection and inflammation in cervical cancer. Pathogens Disease. 2019;77(5). https://doi.org/10.1093/femspd/ftz048 . [Pubmed] [Google scholar] [CrossRef].
Rasi Bonab F, Baghbanzadeh A, Ghaseminia M, Bolandi N, Mokhtarzadeh A, Amini M, et al. Molecular pathways in the development of HPV-induced cervical cancer. EXCLI J. 2021;20:320–37. https://doi.org/10.17179/excli2021-3365 . [Pubmed] [Google scholar] [CrossRef].
doi: 10.17179/excli2021-3365
pubmed: 33746665
pmcid: 7975633
Boccardo E, Lepique AP, Villa LL. The role of inflammation in HPV carcinogenesis. Carcinogenesis. 2010;31(11):1905–12. https://doi.org/10.1093/carcin/bgq176 . [Pubmed] [Google scholar] [CrossRef].
Despot A, Fureš R, Despot AM, Mikuš M, Zlopaša G, D’Amato A, et al. Reactive oxygen species within the vaginal space: an additional promoter of cervical intraepithelial neoplasia and uterine cervical cancer development? Open Med. 2023;18(1). https://doi.org/10.1515/med-2023-0826 . [Pubmed] [Google scholar] [CrossRef].